Pub­lic com­bat over US drug prices cen­ters on Prop 61 as rhetoric heats up to fever pitch

A week ago, Propo­si­tion 61 looked like a sure win­ner for its ad­vo­cates. With sen­ti­ment run­ning strong­ly against Big Phar­ma com­pa­nies, polls showed plen­ty of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA